USFDAAug 5, 2026, 07:04 AM
Lexeo Therapeutics LX2020 Receives FDA RMAT Designation
AI Summary
Lexeo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020, its investigational gene therapy for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). This designation is based on recent interim clinical data from the ongoing HEROIC-PKP2 Phase I/II clinical trial. LX2020 now holds RMAT, Orphan Drug, and Fast Track designations, which are expected to facilitate its development and review process, potentially leading to accelerated approval for this serious condition with unmet medical needs.
Key Highlights
- Lexeo Therapeutics' LX2020 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
- RMAT designation is based on recent interim clinical data from the ongoing HEROIC-PKP2 Phase I/II clinical trial.
- LX2020 now holds RMAT, Orphan Drug, and Fast Track designations by the FDA.
- RMAT designation provides enhanced opportunities for interaction with the FDA and potential eligibility for accelerated approval.
- LX2020 is an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM).
- PKP2-ACM is estimated to affect approximately 60,000 people in the United States.
Price Impact
More from LXEO